We are delighted to announce the acquisition of DGr Pharma, by Symeres, a mid-sized, transatlantic contract research and development organisation (CRO/CDMO) specialising in small-molecule drug discovery and development. Download Press Release With headquarters in the Netherlands and operations across Europe and the United States, Symeres offers over 30 years of industry experience and serves biotech […]
As of December 16, 2024, our company is located in Breda. New address: Hoge Mosten 2 C1, 4822 NH Breda
We are looking for a Senior Consultant Clinical Pharmacology and Pharmacokinetics to join our team. If you are interested, please visit LinkedIn
The DGr Pharma team is pleased to announce having obtained the endorsement of GLP compliance for the conduct of pharmacokinetic and toxicokinetic analyses after successfully passing again the GLP inspection by the Dutch GLP authority (IGJ). Please refer to the
View some publications in which DGr Pharma is involved… Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema TreatmentUsing Bradykinin-B2-Receptor Antagonists PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans